Cross-sectional study
Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Risk Factors Under the Inflation Reduction Act
- Cross-sectional study
Authors' conclusion
More than 1 million older adults with CV risk factors and/or conditions spend >$2,000/year out-of-pocket on prescription drugs and will likely benefit from the Inflation Reduction Act's cap, with estimated total out-of-pocket savings of $1.7 billion/year, while another 1.3 million will also become newly eligible for LIS.
Study context
- Population
- Medicare beneficiaries aged ≥65 years with ≥1 cardiovascular (CV) risk factor/condition, 2016–2019annual estimate, ± 855,653 (mean ± SE)
- Participants
- 34,056,335 beneficiaries
- Outcome
- Beneficiaries with out-of-pocket prescription drug costs >$2,000/year and their potential savings under the Inflation Reduction Act's spending cap
Main finding
As reported in the abstract
Beneficiaries with out-of-pocket drug costs >$2,000/year (mean ± SE)
1,020,484 ± 77,055
Estimated median out-of-pocket drug savings under the Inflation Reduction Act
$855/year
Total annual savings (± SE)
$1,723,031,307 ± $91,150,609
Observational data: associations, not effects.
Further findings
| Outcome | adjusted OR (95% CI) | |
|---|---|---|
| Out-of-pocket drug costs >$2,000/year by age | 0.67 (0.49–0.93) | |
| 0.512Adjusted odds ratio (log scale) |
Out-of-pocket drug costs >$2,000/year by age
- Lower likelihood for low-income vs higher-income adults
Newly eligible for low-income subsidies (LIS) under the Inflation Reduction Act
- Beneficiaries newly eligible for LIS
- 1,289,861
Original publication
Summarised from the published abstract; every number is checked against it